Bicara Therapeutics Advances Ficerafusp Alfa into Phase 3, Eyes 2027 Interim Readout
Event summary
- Bicara Therapeutics selected 1500mg weekly as the optimal dose for ficerafusp alfa and initiated Phase 3 of the FORTIFI-HN01 pivotal trial, with interim analysis expected mid-2027.
- The company announced plans to develop a less frequent loading and every-three-week maintenance dose of ficerafusp alfa.
- Bicara raised $161.8 million in net proceeds through an oversubscribed public offering in Q1 2026.
- Cash, cash equivalents, and marketable securities totaled $414.8 million as of December 31, 2025, with a runway into the first half of 2029.
- Research and development expenses increased to $125.1 million for the full year 2025, up from $63.6 million in 2024.
The big picture
Bicara Therapeutics is advancing its lead candidate, ficerafusp alfa, through pivotal clinical trials aimed at treating HPV-negative head and neck cancer. The company's strategic focus on optimizing dosing schedules and securing regulatory alignment underscores its commitment to transforming outcomes for patients. With a robust financial position and a clear path toward potential commercialization, Bicara is positioning itself as a key player in the biopharmaceutical industry.
What we're watching
- Clinical Progress
- The pace at which Bicara Therapeutics achieves substantial enrollment in the FORTIFI-HN01 pivotal study will determine the timeline for the interim analysis readout in mid-2027.
- Regulatory Alignment
- Whether Bicara can secure regulatory alignment for the less frequent dosing schedule of ficerafusp alfa will be critical for potential U.S. approval.
- Commercial Readiness
- The company's ability to make critical commercial hires, including a Chief Commercial Officer, by the end of 2026 will be key to advancing organizational preparation for launch readiness.
Related topics